Major Clene Insider Makes a Big Move With Eye-Catching Stock Sale
TipRanks (Wed, 13-May 10:07 PM ET)
Presenting on Emerging Growth Conference 92 Day 2 on May 7; Register to live stream
Globe Newswire (Wed, 6-May 7:00 AM ET)
Clene Announces $7 Million Underwritten Offering of Common Stock
Globe Newswire (Tue, 5-May 8:45 AM ET)
Clene to Present at Upcoming May Conferences
Globe Newswire (Tue, 5-May 8:00 AM ET)
Presenting on Emerging Growth Conference 92 Day 1 on May 6; Register to live stream
Globe Newswire (Tue, 5-May 7:00 AM ET)
FDA Opens Door for Clene’s Accelerated ALS Therapy Approval—What’s the Big Deal for CLNN?
Market Chameleon (Mon, 4-May 5:56 AM ET)
Clene’s Fast Track with FDA Accelerates ALS Drug CNM-Au8 Toward Approval—NfL Biomarker at the Center
Market Chameleon (Mon, 4-May 4:35 AM ET)
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS
Globe Newswire (Mon, 4-May 8:00 AM ET)
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
Globe Newswire (Thu, 12-Mar 8:00 AM ET)
Presenting on Emerging Growth Conference 90 Day 2 on February 26; Register to live stream
Globe Newswire (Wed, 25-Feb 7:00 AM ET)
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Clene trades on the NASDAQ stock market under the symbol CLNN.
As of May 13, 2026, CLNN stock price was flat at $6.50 with 157,380 million shares trading.
CLNN has a beta of 2.59, meaning it tends to be more sensitive to market movements. CLNN has a correlation of 0.06 to the broad based SPY ETF.
CLNN has a market cap of $76.56 million. This is considered a Micro Cap stock.
Last quarter Clene reported $77,000 in Revenue and -$.88 earnings per share. This beat revenue expectation by $48,500 and missed earnings estimates by -$.33.
In the last 3 years, CLNN traded as high as $21.80 and as low as $2.28.
The top ETF exchange traded funds that CLNN belongs to (by Net Assets): VTI, VXF.
CLNN has outperformed the market in the last year with a price return of +146.2% while the SPY ETF gained +27.8%. CLNN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +53.7% and +12.1%, respectively, while the SPY returned +9.1% and +4.3%, respectively.
CLNN support price is $5.96 and resistance is $7.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLNN shares will trade within this expected range on the day.
